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Background: Hyperhomocysteinemia is a well-known cardiovascular risk factor and its elevation is established in
overt hypothyroidism. Since some authors suggest that chronic autoimmune thyroiditis per se may be considered
as a novel risk factor of atherosclerosis independent of thyroid function, the analysis of classical cardiovascular
risk factors might be helpful in evaluation the causative relationship. Data concerning the impact of thyroid
autoimmunity in euthyroid state on homocysteine (Hcy) level is lacking. The aim of this study was to evaluate Hcy
level in context of anti-thyroperoxidase antibodies (TPOAbs) in euthyroidism.
Methods: It is a case–control study. 31 euthyroid women treated with levothyroxine (L-T4) due to Hashimoto
thyroiditis (HT) and 26 females in euthyroidism without L-T4 replacement therapy were enrolled in the study. All
women with HT had positive TPOAbs. Forty healthy females negative for TPOAbs comparable for age and body
mass index (BMI) participated in the study as controls. Exclusion criteria were a history of any acute or chronic
disease, use of any medications (including oral contraceptives and vitamin supplements), smoking, alcoholism.
Results: TPOAbs titers were higher in both groups of HT patients versus the healthy controls. Hcy levels were
found to be significantly lower in treated HT patients (Me 11 μmol; IQR 4.2 μmol) as compared with healthy
controls (Me 13.35 μmol; IQR 6.34 μmol; p = 0.0179). In contrast, no significant difference was found between non
treated HT and control group in Hcy level. The study groups and the controls did not differ in age and BMI.
Furthermore, levels of TSH, FT4, TC, LDL, HDL and TAG did not differ between the study group and the control
group.
Conclusion: The main finding of the study is a decrease in Hcy level in treated HT as compared with healthy
controls. Based on our observations one can also assume that correct L-T4 replacement was associated here with a
decrease of Hcy. Furthermore, it seems that non treated HT in euthyroidism is not associated with Hcy increase, in
contrast to overt hypothyroidism. This may be just another argument against the concepts about the role of
“euthyroid HT” in the development of atherosclerosis.
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Homocysteine (Hcy) is a sulfur-containing amino acid
naturally found in human blood and its metabolism is
based on two divergent pathways: transsulfuration and
remethylation [1]. Hcy has been investigated as a risk fac-
tor for cardiovascular disease since 1969, when McCully
observed that two patients with homocystinuria were af-
fected with extensive atherosclerosis and arterial throm-
bosis [2]. Since the association between elevated level of
Hcy and increased risk of coronary heart disease was
established [3,4], the issue whether there is a causal rela-
tion still remains unclear [5,6].
To date, hypothyroidism is considered as an independ-
ent risk factor for atherosclerosis. However, the athero-
genic lipid profile does not fully explain the increased
cardiovascular morbidity in hypothyroid individuals. For
that reason, the possible association between hypothy-
roid state and Hcy concentration was suggested. Inter-
estingly, increased Hcy level in overt hypothyroidsm
was found in many studies [7-9]. Additionally, norma-
lization of Hcy level was achieved after euthyroidism
restoration [10]. In sharp contrast with the above men-
tioned results, decreased Hcy concentration was found in
hyperthyroidism [11].
The possible mechanism responsible for increased Hcy
level in hypothyroidism also remains a matter of recent
debate. Firstly, the observed hyperhomocysteinemia may
reflect impaired renal Hcy clearance. Hypothyroidism
probably reduces glomerular filtration rate leading to
increased creatinine and Hcy levels [12-14]. Secondly,
impaired liver metabolism of Hcy linked with hypo-
thyroidism may contribute to hyperhomocysteinemia.
Decreased activity of both enzymes, methionine synthase
and methylenetetrahydrofolate reductase was established
in thyroidectomized rats and may also explain the elevated
level of Hcy in hypothyroidism [15-17].Table 1 Characteristics of the study groups and the controls
Non treated Hashimoto (n = 26) Treat
Age (yr) 43 (17) 38 (18
BMI (kg/m2) 22.8 (3.6) 22.6 (
TSH (mU/L) 1.64 (2.08) 2.07 (
FT4 (pmol/L) 14.7 (2.27)a 17.13
TPOAbs (IU/mL) 242 (290)b 300 (3
Hcy (μmol) 11 (4.2)a,b 10.8 (
[Mean ± SD] [10.33 ± 3.36]a,b [9.84
TC (mg/dl) 207 (64) 205 (6
LDL (mg/dl) 118.5 (50.6) 121 (4
HDL (mg/dl) 57 (30) 67 (16
TAG (mg/dl) 75 (38) 83 (47
Results are expressed as medians, followed by interquartile ranges given in bracket
a,b – values followed by the same letters do not differ significantly at p < 0.05.In contrast to overt thyroid disorders, data concerning
Hcy concentration among patients with subclinical hy-
pothyroidism (SH) is contradictory. Some studies showed
that, despite atherogenic lipid profile in SH, Hcy level is
not increased [18,19]. On the other hand, Hcy concentra-
tion was reported to be higher as compared with euthy-
roid controls [20].
In view of those controversies, and considering the
fact that numerous thyroid disorders are caused by auto-
immune disturbances, we hypothesized that it might be
the autoimmunity against thyroid gland that initially af-
fects Hcy production, even in pre-clinical phases of thy-
roid disorders. Therefore, the aim of this study was to
evaluate Hcy level in context of anti-thyroperoxidase anti-
bodies (TPOAbs) rather than thyroid function. To achieve
this goal, Hcy concentration was determined in otherwise
healthy and euthyroid women with, and without chronic
autoimmune thyroiditis. The criterion of euthyroidism let
us exclude the possible influence of thyroid dysfunction
per se on Hcy concentrations.
Methods
Thirty one euthyroid women treated with levothyroxine
(L-T4) due to Hashimoto thyroiditis (HT) at the out-
patient clinic of the Department of Endocrinology, Me-
tabolism and Internal Medicine and twenty six females
with chronic autoimmune thyroiditis in euthyroidism
without L-T4 replacement therapy were enrolled in the
study (Table 1). All women with HT had positive TPOAbs.
Forty healthy females negative for TPOAbs comparable
for age and body mass index (BMI) participated in the
study as controls (Table 1).
All subjects and controls were euthyroid, either spon-
taneously, or under L-T4 medication. None of the patients
and the controls had a history of any acute or chronic
disease, including diabetes mellitus, hypertension, anginaed Hashimoto (n = 31) Controls (n = 40) p
) 35.5 (15) ns
4) 21.8 (5.40) ns
3.14) 1.54 (1.5) ns
(5.11)b 15.52 (2.23)a,b p = 0.0019
91)b 9 (5.5)a p < 0.0001
6.9)a 13.35 (6.34)b p = 0.0179
± 4.24]a [12.97 ± 6.71]b
0) 196 (51) ns
5.6) 110.9 (37.4) ns
) 65 (15.5) ns
) 82 (46) ns
s.
Figure 1 FT4 concentrations in non treated and treated HT and
in controls.
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sion criteria were also use of any medications (including
oral contraceptives and vitamin supplements), smoking,
alcoholism.
All subjects underwent physical examination with re-
cording of height, weight, heart rate, systolic and diasto-
lic blood pressure. Blood samples were obtained after an
overnight fast. In patients with HT blood samples were
drawn before the ingestion of usual morning L-T4 medi-
cation. Serum levels of thyrotropin hormone (TSH), free
thyroxine (FT4), TPOAbs, Hcy, total cholesterol (TC),
low-density lipoprotein (LDL), high-density lipoprotein
(HDL), triacylglycerol (TAG) were evaluated.
TSH and FT4 were measured using the electrochemilu-
minescence technique in Cobas E 601 (norm ranges: TSH
0.27–4.2 mU/l; FT4 11.5–21.0 pmol/l). TPOAbs were
measured by radioimmunoassay (norm range: <34 IU/ml).
Serum Hcy levels were assessed by high-performance
liquid chromatography (HPLC). The analyzed plasma
thiol compounds (Hcy, Fluka Germany) were diluted
with water at 2:1 ratio and reduced using 1% TCEP
(Tris-(2-carboxyethyl)-phosphin-hydrochloride; Applichem,
Germany) at 1:9 ratio. Subsequently, the sample was de-
proteinized using 1 M HClO4 (at 2:1 ratio) and applied to
the HPLC/EC system.
To determine thiol concentration the samples were
fed to the HPLC system (P580A; Dionex, Germany) cou-
pled to an electrochemical detector (CoulArray 5600;
ESA, USA). The analysis was performed in Termo Hy-
persil BDS C18 column (250 mm × 4.6 mm × 5 μm)
(Germany) in isocratic conditions, using the mobile
phase of 0.15 M phosphate buffer, pH 2.9, supplemented
with 12.5-17% acetonitrile. The system was controlled,
and the data were collected and processed using Chro-
meleon software (Dionex, Germany).
The study was approved by the Poznan University of
Medical Sciences Ethical Commitee, and informed con-
sent was signed by every subject.
Comparison of analyzed parameters between three
groups (HT patients versus healthy controls) was per-
formed by Kruskal-Wallis test with Dunn’s post-hoc
tests because data did not follow normal distribution.
Normality was analyzed by Shapiro-Wilk’s test. Results
were presented as medians and interquartile ranges (IQR).
Spearman’s correlation coefficient was used to measure
the strength of relationship of analyzed parameters. All
tests were performed two-tailed and were considered as
significant at p < 0.05. Statistical analyses were performed
with Statistica 10 (StatSoft Inc., Poland) and MedCalc ver-
sion 10.3.2 (MedCalc Software, Mariakerke, Belgium) .
Results
Descriptive characteristics for the study groups and the
control group are shown in Table 1.The study groups and the controls did not differ in
age and BMI.
TSH levels of treated and non treated HT patients
were similar to those of control subjects. FT4 concentra-
tions of treated HT patients were significantly higher as
compared with non treated HT and did not differ from
controls (Figure 1). TPOAbs titers were higher in both
groups of HT patients versus the healthy controls.
Hcy levels were found to be significantly lower in
treated HT patients as compared with healthy controls
(Figure 2). In contrast, no significant difference was found
between non treated HTand control group in Hcy level.
In treated HT females Hcy level was negatively corre-
lated with age (p = 0.017289; r = −0.42). In contrast, cor-
relation between Hcy and age was not found in non
treated HT and in controls. No significant associations
were found between Hcy and BMI, waist circumference,
TSH, FT4, TPOAbs in all of HT patients and in healthy
females. Furthermore, levels of TC, LDL, HDL and TAG
did not differ between the study groups and the control
group.
Discussion
In this study, we investigated the influence of thyroid
autoimmunity on Hcy concentrations. To achieve this
goal, we used very strict criteria of enrollment, and we
excluded the possible influence of hypothyroidism by
including only patients who were euthyroid, obviously
either spontaneously, or under medication. With this
novel approach, we came to somewhat surprising conclu-
sions that we discuss beneath.
We showed here that non treated HT and treated HT
females had comparable TPOAbs, however treated HT
group had higher level of FT4. Moreover, FT4 in treated
HT and healthy controls did not differ indicating suffi-
cient replacement therapy. The main finding of the study
is a decrease in Hcy level in treated HT as compared
with healthy controls.
Figure 2 Hcy levels in non treated and treated HT and in
controls.
Owecki et al. BMC Endocrine Disorders 2014, 14:18 Page 4 of 6
http://www.biomedcentral.com/1472-6823/14/18Obviously, our findings should be understood in a
broader context of the association between thyroid auto-
immunity and atherosclerosis. Indeed, some authors sug-
gest that chronic autoimmune thyroiditis per se may be
considered as a novel risk factor of atherosclerosis inde-
pendent of thyroid function [21-24]. Currently, however,
the causative relationship between thyroid autoimmunity
and increased risk of atherosclerosis has not yet been
established. A few studies which were addressing this
question investigated the effect of thyroid autoimmunity
on lipid profile, abdominal obesity, fasting glucose and
homeostasis model assessment (HOMA) insulin resist-
ance, as well as carotid intima-media thickness (CIMT)
[25-27]. However, in contrast to our study group, the
study populations were not uniform, therefore the con-
clusions of these investigations are not comparable.
Tamer et al. found that euthyroid HT (n = 84) patients
had higher LDL level as compared with controls (n =
150) (p = 0.0042) [25]. Moreover, TPOAbs level was ne-
gatively correlated with HDL (p = 0.031; r = −0.137) and
positively with TAG (p = 0.013; r = 0.158) and waist cir-
cumference (p = 0.048; r = 0.128). Ciccone et al. estab-
lished that overweight or obese women with HT have
increased IMT as compared with controls [27]. They
suggested that the autoimmunity in HT patients is an in-
dependent factor that might accelerate atherosclerosis.
However, they also found that HT patients had higher
TSH levels and lower FT3.
It must be emphasized here that the effect of both
hypothyroidism and hyperthyroidism on Hcy concentra-
tion has been investigated in many studies before. How-
ever, data concerning the impact of thyroid autoimmunity
in euthyroid state on Hcy level is lacking.
To our knowledge, there was only one report of Hcy
in context of thyroid autoimmunity in euthyroid pre-
menopausal females with Hashimoto thyroiditis recently
reported by Topaloglu et al. [26]. In this research, thestudy population was divided into two subgroups: first
with TSH ≤ 2.5 IU/L and second with TSH > 2.5 IU/L.
The controls were age-matched. CIMT was the only one
evaluated parameter that was significantly higher in the
study group regardless of TSH. CIMT was positively
correlated with antithyroglobulin antibodies (p = 0.014;
r = 0.328). In contrast to our results, Hcy level did not
differ between the study and the control groups. How-
ever, in our study the control group had comparable
BMI with the study group, therefore the body weight did
not have any effect on the Hcy comparison. In contrast,
Topaloglu et al. had a control group with BMI much
lower than the study group (p < 0.001). Therefore, the
potential influence of this co-variable on the Hcy ana-
lysis should be taken into consideration. New insight
into the discussed problem was given in recently pub-
lished research concerning Hcy level in patients with
atrophic glossitis or burning mouth syndrome and auto-
immune thyroiditis [28]. Wang et al. found increased
Hcy level in these patients independently of thyroid
function. Majority of the studied group positive for anti-
thyroid antibodies (anti-thyroglobulin antibodies or anti-
thyroid microsomal antibodies) was euthyroid. However,
despite normal thyroid function in 85.8% of investi-
gated individuals abnormal high blood Hcy level was
established. Authors suggested that this finding was
linked with vitamin B12 deficiency confirmed among
this group.
Our study has some strengths and limitations. The
main limitation of the present study is the number of
patients who underwent the evaluation. However, it
should be underlined, that all subjects were euthyroid fe-
males without any comorbidities and they did not take
any medication. The only one difference between treated
HT females and controls were TPOAbs. In our opinion,
the homogeneity of subjects examined was the strength
of this work that could balance its limitations.
Serum FT4 concentration is considered as an indepen-
dent determinant of Hcy level [29]. As was mentioned
above, Hcy level is generally decreased in hyperthyroid
patients in contrast to hypothyroid subjects, who have
higher Hcy concentration. Moreover, restoration of thy-
roid function leads to normalization of Hcy concen-
tration. In general, our study and control groups were
euthyroid, but this state was achieved by L-T4 replace-
ment therapy in a group of treated HT women. This
group had lower Hcy levels than normal controls, despite
similar FT4 levels. A possible explanation of this finding is
the fact that, in spite of similar hormone concentrations,
these patients differed in that had different sources of
thyroxine: it was endogenous in one group, and exo-
genous in the other. In our opinion, there is a causa-
tive relationship between L-T4 replacement therapy and
decreased Hcy levels. Patients who are on L-T4 therapy
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from pharmacokinetic properties of this medication. The
maximum FT4 concentration occurs approximately two
hours after the drug ingestion [30]. Moreover, there is a
transient increase of FT4 serum level after ingestion of
L-T4 for 5 hours [31]. Since FT4 directly influences Hcy
concentration, during this time Hcy metabolism is similar
to hyperthyroid state and it may lead to decreased Hcy
levels in treated HT patients in contrast to healthy con-
trols, in whom FT4 output is adjusted to real needs and
the rate of physiological elimination .
Conclusions
The main finding of the study is a decrease in Hcy level
in treated HT as compared with healthy controls. Our
study adds further evidence to the debate on possible as-
sociation between chronic autoimmune thyroiditis and
atherosclerosis. It seems that non treated HT in euthyr-
oidism is not associated with Hcy increase, in contrast
to overt hypothyroidism. This may be just another argu-
ment against the concepts about the role of “euthyroid
HT” in the development of atherosclerosis, which is of
quite importance considering the high prevalence of
high TPOAbs titers in Europe. Furthermore, that Hcy
was lower in the treated group may point to the benefi-
cial role of L-T4 treatment in general. Correct L-T4 re-
placement was associated here with a decrease of Hcy.
In conclusion, L-T4 treatment may further add to med-
ical approach aimed at atherosclerosis risk reduction
with regard to Hcy decrease in L-T4-treated women with
chronic autoimmune thyroiditis. This last concept, how-
ever, as drawn only from a cross-sectional setting, requires
further investigation in observational studies.
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